How Patrys’ Injectable Quetiapine Could Transform the $2B Delirium Market
Patrys Limited is advancing a proprietary injectable formulation of quetiapine aimed at the large and underserved delirium treatment market, leveraging an accelerated FDA approval pathway and extensive existing safety data.
- Injectable quetiapine reformulation targets ICU delirium market valued over US$2 billion
- Accelerated FDA 505(b)(2) regulatory pathway with 3–5 year development timeline
- Development costs estimated at $20–30 million, significantly lower than new drug discovery
- Patent protection secured until approximately 2042 for proprietary formulation
- Clinical milestones planned through 2028, including Phase 1A and 1B trials
A Clear Market Opportunity
Delirium, a severe and acute brain dysfunction affecting up to 80% of ICU patients, remains a significant unmet medical need with no currently approved drug treatments. Patrys Limited (ASX:PAB) is positioning itself to address this gap by reformulating quetiapine, a well-known atypical antipsychotic, into a proprietary injectable form designed specifically for ICU, palliative, and aged care settings. This market is estimated to be worth over US$2 billion annually, underscoring the commercial potential of a faster-acting, safer treatment option.
Innovating with a Proven Drug
Quetiapine’s established clinical profile and extensive human safety data provide Patrys with a significant advantage. The reformulated injectable version offers immediate onset of action compared to the oral form, which typically takes 1-2 hours and is difficult to administer to delirium patients. This innovation is protected by a patent extending to around 2042, creating a defensible intellectual property position that supports premium valuation and limits competition.
Accelerated and Cost-Efficient Development
Patrys is pursuing the FDA’s 505(b)(2) regulatory pathway, which allows reliance on existing clinical data to streamline approval. This approach is expected to reduce development time to 3-5 years and costs to approximately $20-30 million; dramatically less than the typical $1.2 billion and decade-plus timeline required for new drug discovery. The company’s clinical plan includes Phase 1A trials in healthy volunteers and Phase 1B safety studies in ICU patients, with key milestones scheduled through 2028.
De-Risking the Investment
Compared to traditional biotech ventures, Patrys’ injectable quetiapine program is structurally de-risked across multiple dimensions. Manufacturing is already established at commercial scale, eliminating scale-up risks. The absence of approved delirium drugs means Patrys is not competing against entrenched incumbents, and the clear unmet need supports strong market demand. Furthermore, the reformulation is designed to fit clinical workflows, enhancing adoption potential and reimbursement prospects.
Experienced Leadership and Corporate Positioning
Patrys’ board combines expertise in biotech, clinical development, and capital markets, with directors experienced in ASX governance, clinical trials, and healthcare investment. The company currently holds a market capitalisation of around $15 million with a cash balance of $1.9 million as of December 2025, positioning it to advance its clinical program through near-term milestones. Investors will be watching closely as Patrys progresses through its Phase 1 trials and regulatory submissions over the next two years.
Bottom Line?
Patrys’ injectable quetiapine could redefine delirium treatment, but clinical and regulatory milestones ahead will be critical to watch.
Questions in the middle?
- Will Patrys secure additional funding to support clinical trials beyond Phase 1B?
- How will the injectable formulation perform in efficacy and safety compared to off-label treatments?
- What partnerships or licensing deals might Patrys pursue to accelerate commercialisation?
